In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
AstraZeneca $AZN has picked up another key win for its cancer drug franchise.
The FDA approved its PARP inhibitor Lynparza for BRCA-mutated metastatic breast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
